This study aimed to investigate the clinical application of rapid on-site evaluation (ROSE) technology in the diagnosis of respiratory system tumors. A total of 175 consecutive hospitalized patients with a suspected respiratory system tumors between 2019 and 2024 were enrolled (124 from 2019 to 2022, and 20 from 2022 to 2024). Here, 144 cases underwent conventional pathological examination with ROSE assistance, while 31 patients received examination without ROSE. The concordance rate between ROSE and pathological results was compared, along with the timeliness of reports from 2019 to 2022. Using pathological examination results as the "gold standard," the difference in diagnostic positive rates between the groups with and without ROSE was compared. The concordance rate between ROSE and pathological diagnosis was 95.83%. The median time of DQ staining in 2019–2022 was 8.0 min, and the median time of pathological results was 5645.5 min, with statistical difference between the two groups (P 0.05). ROSE technology demonstrated a higher positive rate, thereby improving the pathological diagnostic yield compared to conventional pathological examination alone. This enables clinicians to obtain preliminary diagnoses earlier, guides sampling site and quantity, possesses considerable clinical value, and warrants promotion.
Hong et al. (Thu,) studied this question.